Alturas Minerals Corp

Altimmune, Inc. completes End-of-Phase 2 Meeting with FDA, agreeing on Phase 3 program for pemvidutide in obesity treatment. The program includes four 60-week, randomized, double-blind, placebo-controlled trials, enrolling 5,000 subjects to evaluate 1.2 mg, 1.8 mg, and 2.4 mg doses of pemvidutide. The trials aim to assess weight loss, lipid levels, liver fat, and body composition, leveraging pemvidutide's balanced GLP-1/glucagon dual agonism.

Altimmune, Inc. announces successful End-of-Phase 2 Meeting with FDA, aligning on Phase 3 program for pemvidutide in obesity treatment. The program includes four 60-week, randomized, double-blind, placebo-controlled trials, evaluating 1.2 mg, 1.8 mg, and 2.4 mg doses of pemvidutide, aiming to enroll 5,000 subjects. The trials focus on weight loss, lipid reduction, liver fat reduction, and lean mass preservation.

Demand for GLP-1 agonist drugs has surged, leading to supply shortages and increased manufacturing investments. The global GLP-1 receptor agonist market is expected to exceed $55 billion by 2031. Multiple companies, from startups to established players, are developing new GLP-1 drugs, including next-generation medicines with multiple drug targets.

Oprah Winfrey reflects on the impact of weight-loss drugs like Wegovy and Zepbound, which dominate the obesity market. The rise of GLP-1 drugs, initially for diabetes, has led to a 'silent revolution' in obesity treatment. Competition is heating up, with 16 new drugs expected by 2031. Small-cap companies like Viking Therapeutics and Terns Pharmaceuticals are emerging as key players, focusing on oral drugs and new therapeutic targets. Investors are advised to consider long-term efficacy and side effect management.

BioAge Labs, a biopharmaceutical company, recently completed its IPO, raising $238.3 million. Its weight loss candidate, azelaprag, aims to help patients lose weight while retaining muscle mass, differentiating it from existing GLP-1 agonists like Ozempic and Mounjaro. While BioAge Labs faces competition from companies like Abbott Laboratories and Altimmune, it remains a high-risk, high-reward opportunity due to its clinical-stage status and potential FDA approval delays.

Altimmune completes enrollment in IMPACT trial for pemvidutide in MASH, with top-line data expected Q2 2025. End-of-Phase 2 meeting with FDA for obesity program scheduled for November 2024. Plans to submit IND applications for pemvidutide in up to three additional indications starting Q4 2024.

New entrants challenge Novo Nordisk and Eli Lilly in the $200 billion GLP-1 market, with 68% of sales from weight loss by 2031. Novo and Lilly expected to retain 70% of the market but are viewed as overvalued. Next-gen obesity drugs from Roche, Amgen, Pfizer, AstraZeneca, Boehringer, and others will disrupt the market, pressuring pricing. Novo and Lilly's next-gen pipelines also advancing. Public and private firms accelerating obesity drug development through acquisitions and innovative startups.

The weight-loss treatment market is expected to see 16 new drugs by 2029, expanding the market to $200 billion by 2031, driven by interest sparked by Novo Nordisk and Eli Lilly. Amgen and Pfizer are among companies testing their drug candidates, which could lower prices amid criticism over high costs.